Cg Oncology, Inc. (CGON) — 8-K Filings

8-K Filings (15)

• 8-K Filing — Apr 13, 2026
• CG Oncology Relocates HQ, Hints at Officer/Director Changes — Nov 26, 2025 Risk: low
  CG Oncology, Inc. announced on November 22, 2025, a change in its principal executive offices to 400 Spectrum Center Drive, Suite 2040, Irvine, California. This
• CG Oncology Files 8-K — Sep 9, 2025 Risk: low
  CG Oncology, Inc. filed an 8-K on September 9, 2025, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The company, in
• CG Oncology Files 8-K Report — Sep 5, 2025 Risk: low
  On September 5, 2025, CG Oncology, Inc. filed an 8-K report. The filing indicates the company is a biological products developer, incorporated in Delaware, with
• CG Oncology Announces Board and Compensation Changes — Jul 11, 2025 Risk: medium
  CG Oncology, Inc. announced on July 7, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company reported the d
• CG Oncology Reports on Shareholder Vote Matters — Jun 6, 2025 Risk: low
  CG Oncology, Inc. filed an 8-K on June 6, 2025, reporting on a submission of matters to a vote of security holders that occurred on June 5, 2025. The company, i
• CG Oncology & Bristol Myers Squibb Trial Bladder Cancer Combo — Apr 28, 2025 Risk: medium
  CG Oncology, Inc. announced on April 26, 2025, that it has entered into a clinical trial collaboration with Bristol Myers Squibb. This collaboration will evalua
• CG Oncology Files 8-K Report — Mar 24, 2025 Risk: low
  On March 24, 2025, CG Oncology, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure, Other Events, and Financial Statements and Exh
• CG Oncology Appoints New Chief Medical Officer — Jan 10, 2025 Risk: medium
  CG Oncology, Inc. announced on January 9, 2025, the appointment of Dr. Andrew "Andy" Lee as Chief Medical Officer. Dr. Lee, previously a Senior Vice President o
• CG Oncology Files 8-K — Dec 5, 2024 Risk: low
  CG Oncology, Inc. filed an 8-K on December 5, 2024, to report on other events and financial statements. The filing does not contain specific financial figures o
• CG Oncology Files 8-K — May 24, 2024 Risk: low
  CG Oncology, Inc. filed an 8-K on May 24, 2024, to report on several items including Regulation FD disclosures, other events, and financial statements. The fili
• CG Oncology Files 8-K on Operations and Financials — May 9, 2024 Risk: low
  CG Oncology, Inc. filed an 8-K on May 9, 2024, reporting on its results of operations and financial condition, and filing financial statements and exhibits. The
• CG Oncology's Cretostim Gets EU Orphan Drug Status for Bladder Cancer — May 3, 2024 Risk: medium
  CG Oncology, Inc. announced on May 3, 2024, that its investigational drug, cretostim, has been granted Orphan Drug Designation by the European Commission for th
• CG Oncology Reports Executive & Board Changes, Compensation Details — Feb 16, 2024 Risk: medium
  CG Oncology, Inc. filed an 8-K on February 16, 2024, reporting an event that occurred on February 15, 2024. The filing indicates changes in the company's leader
• CG Oncology Confirms Nasdaq Listing for Common Stock (CGON) — Jan 30, 2024
  CG Oncology, Inc. filed an 8-K on January 30, 2024, reporting an event that occurred on January 29, 2024. This filing primarily serves to update the public reco

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX